October 10, 2017
EDO takes another step for Tinostamustine, as first-in-human solid tumor study begins
Mundipharma EDO GmbH (EDO) has begun a US Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid…